Immune response treated with bone marrow mesenchymal stromal cells after stroke

Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zili, Wang, Xudong, Liao, Yidong, Chen, Guangtang, Xu, Kaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530191/
https://www.ncbi.nlm.nih.gov/pubmed/36203971
http://dx.doi.org/10.3389/fneur.2022.991379
_version_ 1784801624477138944
author Wang, Zili
Wang, Xudong
Liao, Yidong
Chen, Guangtang
Xu, Kaya
author_facet Wang, Zili
Wang, Xudong
Liao, Yidong
Chen, Guangtang
Xu, Kaya
author_sort Wang, Zili
collection PubMed
description Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cells (BMSCs) provide a novel strategy for stroke patients. Now, many patients take stem cells to treat stroke. However, the researches of the precise inflammatory mechanism of cell replacement treatment are still rare. In this review, we summarize the immune response of BMSCs treated to stroke and may provide a new perspective for stem cell therapy.
format Online
Article
Text
id pubmed-9530191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95301912022-10-05 Immune response treated with bone marrow mesenchymal stromal cells after stroke Wang, Zili Wang, Xudong Liao, Yidong Chen, Guangtang Xu, Kaya Front Neurol Neurology Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cells (BMSCs) provide a novel strategy for stroke patients. Now, many patients take stem cells to treat stroke. However, the researches of the precise inflammatory mechanism of cell replacement treatment are still rare. In this review, we summarize the immune response of BMSCs treated to stroke and may provide a new perspective for stem cell therapy. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9530191/ /pubmed/36203971 http://dx.doi.org/10.3389/fneur.2022.991379 Text en Copyright © 2022 Wang, Wang, Liao, Chen and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Wang, Zili
Wang, Xudong
Liao, Yidong
Chen, Guangtang
Xu, Kaya
Immune response treated with bone marrow mesenchymal stromal cells after stroke
title Immune response treated with bone marrow mesenchymal stromal cells after stroke
title_full Immune response treated with bone marrow mesenchymal stromal cells after stroke
title_fullStr Immune response treated with bone marrow mesenchymal stromal cells after stroke
title_full_unstemmed Immune response treated with bone marrow mesenchymal stromal cells after stroke
title_short Immune response treated with bone marrow mesenchymal stromal cells after stroke
title_sort immune response treated with bone marrow mesenchymal stromal cells after stroke
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530191/
https://www.ncbi.nlm.nih.gov/pubmed/36203971
http://dx.doi.org/10.3389/fneur.2022.991379
work_keys_str_mv AT wangzili immuneresponsetreatedwithbonemarrowmesenchymalstromalcellsafterstroke
AT wangxudong immuneresponsetreatedwithbonemarrowmesenchymalstromalcellsafterstroke
AT liaoyidong immuneresponsetreatedwithbonemarrowmesenchymalstromalcellsafterstroke
AT chenguangtang immuneresponsetreatedwithbonemarrowmesenchymalstromalcellsafterstroke
AT xukaya immuneresponsetreatedwithbonemarrowmesenchymalstromalcellsafterstroke

Ejemplares similares